Related Experiment Video
Updated: Jun 2, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
iPSC technology: platform for drug discovery. Point
Abstract:
Disease-specific pluripotent stem cells are a source of affected cell types for drug discovery. The ability to reprogram somatic cells into induced pluripotent stem cells (iPSCs) provides a platform for generating cells from patients with different disease severities and drug metabolism responses. Although challenges remain for efficient differentiation and high-throughput scale-up, we propose that iPSCs have distinct advantages over embryonic stem cells (ESCs) for evaluating drugs by performing clinical trials on a dish.
Related Concept Videos
Drug Discovery: Overview
EPS and iPS Cells in Disease Research
Patch Clamp
In this method, a glass micropipette containing electrolyte solution is tightly sealed against a small portion of the cell membrane. As a result, a patch of the cell...
iPS Cell Differentiation
Pharmacogenomics: Identification of New Drug Targets
Induced Pluripotent Stem Cells
